Cancer Epidemiology, Biomarkers & Prevention
Read the current issue of Cancer Epidemiology, Biomarkers & Prevention.
Read the current issue of Cancer Epidemiology, Biomarkers & Prevention.
Are desmoid tumors benign or malignant? How are they diagnosed and treated? And, are they associated with any genetic mutations? Sarcoma specialist Shreyaskumar Patel, M.D.,…
The third prespecified interim analysis of overall survival in the phase III KEYNOTE-564 trial has shown a significant benefit with adjuvant pembrolizumab vs placebo in…
2023 Featured Articles July 13 – Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial Citation: van Hemert,…
Heinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
The ASH Ambassador program supports recruitment and retention of trainees to hematology and to the Society through effective grassroots promotion of ASH’s career development and…
Published: February 13, 2024Written by: Rob LevyWhen Youling Sun was diagnosed in Shanghai, China, with acute myeloid leukemia (AML) in 2018, he called his son,…
Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.
This report describes the development of an 18-gene urine panel for high-grade prostate cancer and validates its external performance relative to current guideline-endorsed biomarkers.
Sara Corvigno, MD, PhD, expands on an analysis that uncovered the CHIP variants that occurred at a higher frequency in patients with ovarian cancer post-chemotherapy.